Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use

Journal of Law, Medicine and Ethics 41 (3):654-664 (2013)
  Copy   BIBTEX

Abstract

The Food and Drug Administration authorizes the marketing of a drug only for uses that the manufacturer has demonstrated to be safe and effective, based on evidence from at least two clinical trials. However, the FDA does not regulate the practice of medicine, so physicians may prescribe drugs in any manner they choose. Prescribing drugs in ways that deviate from the uses specified in the FDA-approved drug label, package insert, and marketing authorization is referred to as off-label prescribing. This occurs when physicians prescribe a drug for a therapeutic purpose other than the one approved by the FDA; treat patients in a different age cohort or gender than the population on which it was tested; or prescribe a different dose, for a different duration of use, or a different mode of administration than indicated on the label.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,709

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Institutional Corruption and the Rule of Law.Paul Gowder - 2014 - Les ateliers de l'éthique/The Ethics Forum 9 (1):84-102.
Speaking Off Label.Stephen R. Latham - 2010 - Hastings Center Report 40 (6):9-10.
Liberal Democratic Institutions and the Damages of Political Corruption.Emanuela Ceva & Maria Paola Ferretti - 2014 - Les ateliers de l'éthique/The Ethics Forum 9 (1):126-145.

Analytics

Added to PP
2016-02-04

Downloads
21 (#734,423)

6 months
13 (#191,601)

Historical graph of downloads
How can I increase my downloads?